Addressing Project Optimus: Use of Preclinical, Modelling, & Clinical Data to Identify the Optimal Dose of the PARP1-Selective Agent Saruparib for Phase 3 Studies
Time: 9:30 am
day: Conference Day 2
Details:
- Interrogating in vitro models to understand mechanisms of action and exposure thresholds for activity
- Analysing in vivo models to understand dose responses and exposure relationships needed for optimal efficacy
- Exploring mathematical quantitative systems pharmacology modeling to correlation of clinical exposures, PD and efficacy in relation to preclinical data and modeling
- Understanding how cross-validation of preclinical results with patient outcomes can drive more effective and personalised cancer treatments
